Gingko Datapoints, a service of Gingko Bioworks, announced Wednesday a collaboration with Inductive Bio and Tangible Scientific aimed at making AI-driven lab-in-the-loop drug discovery more accessible to the biotech and pharmaceutical industries. The partnership will integrate large-scale experimental workflows, streamlined compound management and predictive chemistry AI into an all-in-one platform, enabling researchers to design better drugs faster and with fewer resources.Drug discovery today

Shares in Celldex Therapeutics fell 13% on Wednesday after the company said it will no longer pursue development of its lead candidate, barzolvolimab, in eosinophilic esophagitis (EoE). While the receptor tyrosine kinase KIT inhibitor met its primary endpoint in a Phase II study, achieving "profound" mast cell depletion, that did not correlate to EoE symptom improvements, nor a reduction in disease activity, as compared to placebo."The results do support future development with KIT- or SCF-targe

After dedicating much of its recent R&D efforts to oncology, Jazz Pharmaceuticals recommitted itself to neurology on Wednesday by licensing global, exclusive rights to Saniona's preclinical epilepsy candidate SAN2355.Jazz will shell out $42.5 million upfront and is on the hook for $192.5 million in development and regulatory milestones, including a $7.5 million payment due at the launch of a Phase I study for SAN2355. Saniona is also eligible for up to $800 million in commercial milestones, plus

For the first time in decades, the American Academy of Pediatrics (AAP) has broken rank with the US Centers for Disease Control and Prevention (CDC) over its recommended immunisation schedule for children, specifically around COVID-19 shots. In May, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced that the CDC would remove COVID-19 vaccines from its recommended immunisation schedule for both healthy children and healthy pregnant women. At the time, Kennedy said the polic

The leading US pediatrician group has split with HHS Secretary Robert F. Kennedy Jr. on its vaccine recommendations for kids, recommending the Covid-19 vaccine for all children from 6 months to 2 years of age. The break from the government’s recommendations was reflected in the American Academy of Pediatrics’ updated childhood immunization schedule released Tuesday. The group recommends that all kids 6 to 23 months should receive an updated vaccine this upcoming respiratory season. The CDC recom

iStock, Chitraporn Nakorn In late May, a patient died after receiving Rocket Pharmaceuticals’ investigational gene therapy for Danon disease, spurring the hold. After lowering the dose and changing the regimen of immune modulators patients receive, the company has received FDA clearance for the trial to continue. The FDA has lifted a clinical hold on a Phase II trial testing Rocket Pharmaceuticals’ investigational gene therapy for Danon disease, the company announced Wednesday. The hold was p

iStock, Jacob Wackerhausen The CDC no longer recommends COVID-19 vaccines for healthy children and healthy pregnant women, a position that has been opposed by leading medical societies. The American Academy of Pediatrics recommends that all children aged 6 to 23 months be vaccinated against COVID-19, a stark departure from the revised schedule Health Secretary Robert F. Kennedy Jr. has pushed for. The AAP schedule differs “from recent recommendations of the Advisory Committee on Immunization Pr

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular lymphoma (FL). The phase 3 EPCORE FL-1 trial has been comparing subcutaneous epcoritamab plus rituximab and lenalidomide (R2) against R2 alone in adult patients. The study achieved its dual primary endpoints of overall response rate and progression-free survival, lowering the risk of disease progression or death by 79%. The safety profile of the combination was also found to

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases, today announces that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company’s lead RNA aptamer Apta-1 in new indication areas, based on detailed evaluation of data generated from previous studies with Apta-1. These groundbreaking new insights are based on the detailed evaluation of data generat

CAMBRIDGE, Mass., Aug. 19, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-iden